Business & Finance

Healthcare research firm finds HIV market will expand with new drug therapies

Published in AIDS Weekly, June 27th, 2005

Decision Resources, Inc., a research and advisory firm focusing on pharmaceutical and healthcare issues, finds that the current HIV drug market will expand with the help of recently launched products from Bristol-Myers Squibb and Gilead.

Bristol-Myers Squibb's Reyataz is the first once-daily protease inhibitor that also has a favorable lipid side-effect profile. Gilead's Truvada is a highly potent, well-tolerated, convenient, once-daily fixed-dose combination of 2 non-nucleoside reverse transcriptase inhibitors. Increased uptake of both products will drive overall sales growth in the near term. In the longer term, classes with novel mechanisms of action will expand the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2005-06-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry